POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS

被引:175
作者
ANDERSSON, T
REGARDH, CG
LOU, YC
ZHANG, Y
DAHL, ML
BERTILSSON, L
机构
[1] Research Laboratories, Astra Hässle AB, Mölndal
[2] Department of Pharmacology, Beijing Medical University, Beijing
[3] Department of Clinical Pharmacology, Karolinska Institute, Huddinge Hospital, Huddinge
来源
PHARMACOGENETICS | 1992年 / 2卷 / 01期
关键词
D O I
10.1097/00008571-199202000-00005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Twelve Caucasian healthy men and women, of whom six were poor metabolizers (PMs) and six were extensive metabolizers (EMs) of S-mephenytoin, together with 13 Chinese healthy men and women (five PMs and eight EMs), received a single oral 20 mg dose of omeprazole. Plasma levels of omeprazole and its two main metabolites, omeprazole sulphone and hydroxyomeprazole, were determined by HPLC. The mean (+/-SD) area under the plasma concentration-time curve (AUC) for omeprazole was 11.1 +/- 2.6 and 0.9 +/- 0.4 muM h in the Caucasian PMs and EMs, respectively. Corresponding values for elimination half-life were 2.3 + 0.4 and 0.7 +/- 0.4 h. In the Chinese PMs and EMs the AUC of omeprazole as 13.3 +/- 5.6 and 2.6 +/- 1.8 muM h. The AUCs of omeprazole were significantly higher in the Chinese EMs than in the Caucasian EMs possibly due to the higher proportion of heterozygotes in the former than in the latter group. The elimination half-life in the Chinese PMs and EMs was 2.4 +/- 0.2 and 0.8 +/- 0.2 h -similar to the observations in the Caucasian subjects. The maximum plasma concentration of hydroxyomeprazole was five-fold and four-fold higher in EMs compared to PMs among Caucasians and Chinese, respectively. The elimination half-life of the hydroxy metabolite was also longer in PMs than in EMs in both populations. The ratio between AUC for omeprazole and AUC for hydroxyomeprazole was 11.9 +/- 2.1 and 0.6 +/- 0.1 in Caucasian PMs and EMs, respectively. Corresponding values in the Chinese were 13.1 +/- 2.9 and 1.6 +/- 0.5. The AUCs of the sulphone metabolite were higher in PMs than in EMs among both Caucasians and Chinese. A longer half-life of the sulphone was also found in PMs compared to EMs. It is concluded that a major metabolic pathway of omeprazole, the formation of hydroxyomeprazole and at least partly also its elimination, cosegregates with the polymorphic metabolism of S-mephenytoin in both Caucasians and Chinese. The elimination, and perhaps part of the formation, of omeprazole sulphone also appears to be dependent on this polymorphic enzyme.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 27 条
[1]  
Andersson T., Pharmacokinetics of omeprazole in man
[2]  
with special reference to single and repeated administration, drug interactions, and polymorphic metabolism, Thesis No: ISBN 91-628-0180-5
[3]  
University of Goteborg, (1991)
[4]  
Andersson T., Ren K., Cederberg C., Heggelund A., Rohss K., Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seventh day of treatment, Drug Invest, 2, pp. 184-188, (1990)
[5]  
Andersson T., Ren K., Cederberg C., Lagerstrom P.O., Lund- Borg P., Skanberg I., Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects, Br J Clin Pharmacol, 29, pp. 557-563, (1990)
[6]  
Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P., Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolisers of omeprazole, Clin Pharmacol Ther, 47, pp. 79-85, (1990)
[7]  
Andersson T., Cederberg C., Regardh C.G., Skanberg I., Pharmacokinetics of different single intravenous and oral doses of omeprazole, Pur J Clin Pharmacol, 39, pp. 195-197, (1990)
[8]  
Andersson T., Cederberg C., Heggelund A., Lundborg P., The pharmacokinetics of single and repeated once daily doses of 10, 20 and 40 mg omeprazole as enteric coated granules, Drug Invest, 3, pp. 45-52, (1991)
[9]  
Andersson T., Regardh C.G., Dahl-Puustinen M.L., Bertilsson L., Slow omeprazole metabolisers are also poor S-mephenytoin hy- droxylators, Ther Drug Monit, 12, pp. 415-416, (1990)
[10]  
Bardhan K.D., Bianchi Porro G., Bose K., Daly M., Hinchliffe R., Jonsson E., Lazzaroni M., Naesdahl J., Rikner L., Walan A., A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcer, J Clin Gastroenterol, 8, pp. 408-413, (1986)